Clinical trials
Observational Wet Macular Degeneration trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 7 |
| Johns Hopkins University | 2 |
| Adverum Biotechnologies, Inc. | 1 |
| Centre Hospitalier Intercommunal Creteil | 1 |
| Centre Hospitalier Régional Metz-Thionville | 1 |
| Guy's and St Thomas' NHS Foundation Trust | 1 |
| Ospedale Santa Croce-Carle Cuneo | 1 |
| Shanghai University of Traditional Chinese Medicine | 1 |
| Sorlandet Hospital HF | 1 |
| The Retina Center of St. Louis County, PC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Wet Macular Degeneration | 17 |
| Macular Degeneration | 3 |
| Choroidal Neovascularization | 2 |
| Eye Diseases | 2 |
| Blindness | 1 |
| Geographic Atrophy | 1 |
| Retinal Degeneration | 1 |
| Retinal Diseases | 1 |
| Retinal Drusen | 1 |
| Retinal Vein Occlusion | 1 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.